Product Description: Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research[1].
Applications: Neuroscience-Neurodegeneration
Formula: N/A
References: [1]Matthew E Barton, et al. Design of a patient- and investigator-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of bepranemab, UCB0107, in prodromal to mild Alzheimer’s disease: The TOGETHER Study, AH0003. Alzheimer's & Dementia. 31 December 2021.
CAS Number: 2244960-75-4
Molecular Weight: N/A
Compound Purity: 99.79
Research Area: Neurological Disease
Solubility: 10 mM in DMSO
Target: Tau Protein